BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Prostate cancer AND SPOP, TEF2, 8405, ENSG00000121067, O43791 AND Diagnosis
15 results:

  • 1. Metastatic prostate cancer is associated with distinct higher frequency of genetic mutations at diagnosis.
    Al-Toubat M; Serrano S; Elshafei A; Koul K; Feibus AH; Balaji KC
    Urol Oncol; 2023 Nov; 41(11):455.e7-455.e15. PubMed ID: 37838503
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Somatic and Germline Variants Affect Prognosis and Susceptibility in prostate cancer.
    Rocca C; Rocca G; Zampieri P; Dell'atti L; Bianchi N; Ippolito C; Aguiari G
    Anticancer Res; 2023 Jul; 43(7):2941-2949. PubMed ID: 37351993
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Molecular features and race-associated outcomes of spop-mutant metastatic castration-resistant prostate cancer.
    Stangl A; Wilner C; Li P; Maahs L; Hwang C; Pilling A
    Prostate; 2023 May; 83(6):524-533. PubMed ID: 36604824
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. spop Mutations as a Predictive Biomarker for Androgen Receptor Axis-Targeted Therapy in De Novo Metastatic Castration-Sensitive prostate cancer.
    Swami U; Graf RP; Nussenzveig RH; Fisher V; Tukachinsky H; Schrock AB; Li G; Ross JS; Sayegh N; Tripathi N; Mathew Thomas V; Oxnard GR; Antonarakis ES; Agarwal N
    Clin Cancer Res; 2022 Nov; 28(22):4917-4925. PubMed ID: 36088616
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Genomic Features of Lung-Recurrent Hormone-Sensitive prostate cancer.
    Fonseca NM; Van der Eecken K; Herberts C; Verbeke S; Ng SWS; Lumen N; Ritch E; Murtha AJ; Bernales CQ; Schönlau E; Moris L; Van Dorpe J; Annala M; Wyatt AW; Ost P
    JCO Precis Oncol; 2022 Apr; 6():e2100543. PubMed ID: 35507889
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Tumor subtype defines distinct pathways of molecular and clinical progression in primary prostate cancer.
    Liu D; Augello MA; Grbesa I; Prandi D; Liu Y; Shoag JE; Karnes RJ; Trock BJ; Klein EA; Den RB; Demichelis F; Davicioni E; Sboner A; Barbieri CE
    J Clin Invest; 2021 May; 131(10):. PubMed ID: 33998599
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. TP53 alterations of hormone-naïve prostate cancer in the Chinese population.
    Liu Z; Guo H; Zhu Y; Xia Y; Cui J; Shi K; Fan Y; Shi B; Chen S
    Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):482-491. PubMed ID: 33214693
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Core Biopsies from prostate cancer Patients in Active Surveillance Protocols Harbor PTEN and MYC Alterations.
    Gandellini P; Casiraghi N; Rancati T; Benelli M; Doldi V; Romanel A; Colecchia M; Marenghi C; Valdagni R; Demichelis F; Zaffaroni N
    Eur Urol Oncol; 2019 May; 2(3):277-285. PubMed ID: 31200842
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. spop-Mutated/CHD1-Deleted Lethal prostate cancer and Abiraterone Sensitivity.
    Boysen G; Rodrigues DN; Rescigno P; Seed G; Dolling D; Riisnaes R; Crespo M; Zafeiriou Z; Sumanasuriya S; Bianchini D; Hunt J; Moloney D; Perez-Lopez R; Tunariu N; Miranda S; Figueiredo I; Ferreira A; Christova R; Gil V; Aziz S; Bertan C; de Oliveira FM; Atkin M; Clarke M; Goodall J; Sharp A; MacDonald T; Rubin MA; Yuan W; Barbieri CE; Carreira S; Mateo J; de Bono JS
    Clin Cancer Res; 2018 Nov; 24(22):5585-5593. PubMed ID: 30068710
    [No Abstract]    [Full Text] [Related]  

  • 10. prostate cancer Genomics: Recent Advances and the Prevailing Underrepresentation from Racial and Ethnic Minorities.
    Tan SH; Petrovics G; Srivastava S
    Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29690565
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Bone biopsy protocol for advanced prostate cancer in the era of precision medicine.
    Sailer V; Schiffman MH; Kossai M; Cyrta J; Beg S; Sullivan B; Pua BB; Lee KS; Talenfeld AD; Nanus DM; Tagawa ST; Robinson BD; Rao RA; Pauli C; Bareja R; Beltran LS; Sigaras A; Eng KW; Elemento O; Sboner A; Rubin MA; Beltran H; Mosquera JM
    Cancer; 2018 Mar; 124(5):1008-1015. PubMed ID: 29266381
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Quantification of mutant spop proteins in prostate cancer using mass spectrometry-based targeted proteomics.
    Wang H; Barbieri CE; He J; Gao Y; Shi T; Wu C; Schepmoes AA; Fillmore TL; Chae SS; Huang D; Mosquera JM; Qian WJ; Smith RD; Srivastava S; Kagan J; Camp DG; Rodland KD; Rubin MA; Liu T
    J Transl Med; 2017 Aug; 15(1):175. PubMed ID: 28810879
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Genetic Progression of High Grade Prostatic Intraepithelial Neoplasia to prostate cancer.
    Jung SH; Shin S; Kim MS; Baek IP; Lee JY; Lee SH; Kim TM; Lee SH; Chung YJ
    Eur Urol; 2016 May; 69(5):823-30. PubMed ID: 26542946
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Next-generation sequencing technology in prostate cancer diagnosis, prognosis, and personalized treatment.
    Yadav SS; Li J; Lavery HJ; Yadav KK; Tewari AK
    Urol Oncol; 2015 Jun; 33(6):267.e1-13. PubMed ID: 25791755
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Mutation detection in formalin-fixed prostate cancer biopsies taken at the time of diagnosis using next-generation DNA sequencing.
    Manson-Bahr D; Ball R; Gundem G; Sethia K; Mills R; Rochester M; Goody V; Anderson E; O'Meara S; Flather M; Keeling M; Yazbek-Hanna M; Hurst R; Curley H; Clark J; Brewer DS; McDermott U; Cooper C
    J Clin Pathol; 2015 Mar; 68(3):212-7. PubMed ID: 25586381
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.